CytomX reported positive Phase 1 expansion data from the ongoing CTMX-2051-101 study of varsetatug masetecan (Varseta-M), an EpCAM PROBODY ADC, in late-line metastatic colorectal cancer, with preliminary results as of a Jan. 16, 2026 data cutoff. In efficacy-evaluable patients, confirmed overall response rate was 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W. Estimated median progression-free survival was 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg. In 20 patients treated with an updated diarrhea prophylaxis regimen during dose optimization at 8.6 mg/kg and 10 mg/kg, grade 3 diarrhea occurred in 10%. Additional efficacy and safety results from the Phase 1 study are expected to be presented at one or more medical meetings in 2026, and a Phase 1 combination study with bevacizumab in colorectal cancer has been initiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672541) on March 16, 2026, and is solely responsible for the information contained therein.